ライフサイエンスコーパス: geographic atrophy

1 gression to late AMD (neovascular or central geographic atrophy).

2 ssociated with development or progression of geographic atrophy.

3 luding the dry type of macular degeneration, geographic atrophy.

4 gmented pattern dystrophy appears to predate geographic atrophy.

5 lsewhere, drusen, abnormal pigmentation, and geographic atrophy.

6 tinal damage and vision loss associated with geographic atrophy.

7 thesized causes are being developed to treat geographic atrophy.

8 cular AMD (choroidal neovascularization) and geographic atrophy.

9 ough index cases with neovascular disease or geographic atrophy.

10 were elevated in the RPE in human eyes with geographic atrophy.

11 D and 14.3% (95% CI, 2.0%-42.8%; n = 2) were geographic atrophy.

12 early pseudodrusen and rapid development of geographic atrophy.

13 70-1.26; P = .67) for development of central geographic atrophy.

14 .98 (95% CI, 0.69-1.39; P = .91) for central geographic atrophy.

15 es from five subjects were tested (four with geographic atrophy [66.3 +/- 6.4 years, mean +/- 1 SD] a

16 l death of the retinal pigment epithelium in geographic atrophy, a type of age-related macular degene

17 The RPE of human eyes with geographic atrophy accumulates toxic Alu RNA in response

18 Geographic atrophy affecting the fovea was thought to be

19 pigmented epithelium has been implicated in geographic atrophy, an advanced form of age-related macu

20 Geographic atrophy, an advanced form of age-related macu

21 he advanced stages of AMD, including 58 with geographic atrophy and 62 with neovascular disease.

22 In patients with geographic atrophy and at least 1 year of follow-up, atr

23 Areas of geographic atrophy and choroidal neovascularization imag

24 s of disease progression to be identified in geographic atrophy and may improve understanding of the

25 te AMD lesions, overall and specifically for geographic atrophy and neovascular AMD, compared with th

26 ng the pathogenesis of advanced AMD, in both geographic atrophy and neovascular AMD.

27 s also discriminated risk for progression to geographic atrophy and neovascular disease separately.

28 wo major AMD phenotypes (neovascular AMD and geographic atrophy) and by age of affected family member

29 tation, hypopigmentation), 5 had extrafoveal geographic atrophy, and 1 had exudative AMD.

30 727 cases of late AMD (1151 neovascular, 384 geographic atrophy, and 192 mixed [neovascular AMD and g

31 rder of the retina, characterized by drusen, geographic atrophy, and choroidal neovascularization.

32 ween the RPE and the underlying vasculature, geographic atrophy, and choroidal neovascularization.

33 revalence of early and advanced AMD, drusen, geographic atrophy, and neovascular AMD were determined

34 predominant phenotype based on drusen size, geographic atrophy, and neovascular AMD.

35 e size and extent of drusen, the presence of geographic atrophy, and neovascular changes.

36 or suggestively higher risk of large drusen, geographic atrophy, and neovascularization.

37 pithelium depigmentation; increased pigment; geographic atrophy; and neovascular macular degeneration

38 atrophy, and 192 mixed [neovascular AMD and geographic atrophy]) and 1153 controls.

39 eting all putative phases of pathogenesis in geographic atrophy are under development.

40 btypes of late AMD (neovascular AMD and pure geographic atrophy), assessed in retinal photographs acc

41 ize ongoing and recently completed trials on geographic atrophy associated with age-related macular d

42 tivity was identified in eyes with nonfoveal geographic atrophy at both 6 months (-1.41 dB [0.22 dB];

43 , especially if therapies to slow or reverse geographic atrophy become available.

44 As a fraction of the geographic atrophy border zone, the mean new GA was 0.44

45 gment epithelial atrophy preceded CC loss in geographic atrophy, but CC loss occurred in the absence

46 ks of developing neovascular AMD and central geographic atrophy by 10 years were 48.1% and 26.0%, res

47 h a reduced likelihood of developing central geographic atrophy (CGA) and neovascular (NV) AMD.

48 NRTIs were efficacious in mouse models of geographic atrophy, choroidal neovascularization, graft-

49 A novel parameter called the "Geographic Atrophy Circularity Index" (GACI) was develop

50 All participants in whom geographic atrophy developed during follow-up had visibl

51 At 2 years, geographic atrophy developed in a lower percentage of ey

52 ion of Bruch membrane alterations to CNV and geographic atrophy development in age-related macular de

53 ty, thickness, and gap length in donors with geographic atrophy did not differ from those of controls

54 ipants had intermediate AMD, 8 had nonfoveal geographic atrophy due to AMD.

55 Geographic atrophy enlarged in each eye over time.

56 was defined as newly diagnosed advanced AMD (geographic atrophy, exudative disease, or AMD causing vi

57 fibrosis, pigment epithelium detachment, and geographic atrophy/fibrotic scar/neovascular AMD in the

58 otoreceptor cell loss in late AMD, including geographic atrophy, for which no efficient treatment cur

59 anatomically with the site at which areolar (geographic) atrophy frequently occurs in retinal pigment

60 re scarring (60.0% vs 41.4%, P = .007), more geographic atrophy (GA) (31.6% vs 20.7%, P = .004), larg

61 ociations between the complement pathway and geographic atrophy (GA) (OR, 2.17; 95% CI, 1.12-4.24; P

62 either choroidal neovascularization (CNV) or geographic atrophy (GA) and 53 donor eyes of 53 patients

63 CVA) was compared between late AMD subtypes; geographic atrophy (GA) and choroidal neovascularization

64 The right eye in case 1 had geographic atrophy (GA) and demonstrated a large area in

65 n focally increased autofluorescence (FIAF), geographic atrophy (GA) and focally decreased autofluore

66 on: No AMD, Intermediate AMD, and Late AMD - geographic atrophy (GA) and Late AMD - neovascular (NV).

67 a on age-sex-specific incidence of late AMD, geographic atrophy (GA) and neovascular AMD (NVAMD), yea

68 These changes are reminiscent of geographic atrophy (GA) and point to a role for RPE-deri

69 To correlate the area of geographic atrophy (GA) and residual foveal sparing (FS)

70 AMD is clinically heterogeneous, leading to geographic atrophy (GA) and/or choroidal neovascularizat

71 Eyes with geographic atrophy (GA) at 2 years were correlated with

72 the genetic risk factors that contribute to geographic atrophy (GA) could lead to advancements in in

73 mate the incidence, size, and growth rate of geographic atrophy (GA) during 5 years of follow-up amon

74 rogression or development of junctional zone geographic atrophy (GA) in age-related macular degenerat

75 hod useful for estimating the progression of geographic atrophy (GA) in clinical trials.

76 as the new appearance of neovascular AMD or geographic atrophy (GA) in eyes at risk of late AMD.

77 ctors, incidence, and rate of progression of geographic atrophy (GA) in eyes with neovascular age-rel

78 Geographic atrophy (GA) is an advanced form of age-relat

79 ying degrees with anti-angiogenic drugs, but geographic atrophy (GA) is an advanced stage of the more

80 No effective therapeutic strategy for geographic atrophy (GA) is available, and prevention cou

81 Geographic atrophy (GA) is the end-stage manifestation o

82 Geographic atrophy (GA) is the major cause of blind regi

83 Progressive geographic atrophy (GA) of the retinal pigment epitheliu

84 Appearance of geographic atrophy (GA) on color photography (CP) is pre

85 epithelium (RPE) defects not attributable to geographic atrophy (GA) or RPE-tears with overlying pres

86 (VA), disease progression and vision loss in geographic atrophy (GA) owing to AMD are gradual process

87 AP) study was designed to assess the rate of geographic atrophy (GA) progression and to identify prog

88 a healthy normal eye as well as of eyes with geographic atrophy (GA) secondary to age-related macular

89 ents (n = 71) 50 years of age and older with geographic atrophy (GA) secondary to age-related macular

90 es of adults aged >/=50 years with bilateral geographic atrophy (GA) secondary to age-related macular

91 escent choroidal neovascularization (CNV) in geographic atrophy (GA) secondary to nonexudative age-re

92 nd eventually to neovascular disease (NV) or geographic atrophy (GA) was applied to estimate stage-sp

93 Presence of geographic atrophy (GA) was associated with the highest

94 Geographic atrophy (GA) was associated with worse VA (64

95 ges of choroidal neovascularization (CNV) or geographic atrophy (GA) was evaluated to determine wheth

96 lar degeneration (AMD) and advanced AMD with geographic atrophy (GA) were assayed for AGE and RAGE by

97 In zones 2 and 3, neovascularization and geographic atrophy (GA) were present, ranging from 0.4%

98 of the retinal pigmented epithelium (RPE) in geographic atrophy (GA), a late stage of age-related mac

99 pigmented epithelium (RPE) is implicated in geographic atrophy (GA), an advanced form of age-related

100 Geographic atrophy (GA), an untreatable advanced form of

101 lateral large, soft drusen, with and without geographic atrophy (GA), and 55 fellow eyes of 55 patien

102 color photographs, including drusen volume, geographic atrophy (GA), and preatrophic features, were

103 ee aged control subjects, five subjects with geographic atrophy (GA), and three subjects with wet AMD

104 s with both choroidal neovascularization and geographic atrophy (GA), but few genome-wide scans (GWSs

105 y age-related macular degeneration (AMD), or geographic atrophy (GA), is characterized by extensive r

106 as 8.4%; for late AMD, it was 1.4%; for pure geographic atrophy (GA), it was 0.6%; for exudative AMD,

107 e dry AMD (AREDS stage 3), advanced AMD with geographic atrophy (GA), or neovascular AMD (CNV).

108 m the mean as abnormal, indicating drusen or geographic atrophy (GA), respectively.

109 ry age-related macular degeneration (AMD) or geographic atrophy (GA).

110 ation 4 included neovascular AMD (nvAMD) and geographic atrophy (GA).

111 ies in SD-OCT images of eyes with drusen and geographic atrophy (GA).

112 a 77-year-old nonexudative AMD patient with geographic atrophy (GA).

113 ) of atrophic zones (AZ), which characterize geographic atrophy (GA).

114 y of late, nonexudative AMD is the growth of geographic atrophy (GA).

115 pment of late AMD, either neovascular AMD or geographic atrophy (GA).

116 on, acquired vitelliform lesions (AVLs), and geographic atrophy (GA); and ultrastructural and stainin

117 ne, 22.7% progressed to late AMD (11.0% pure geographic atrophy [GA] and 11.7% exudative AMD).

118 severity groups (from controls to non-foveal geographic atrophy [GA]), and the relationships and magn

119 Geographic atrophy growth depends on several ocular fact

120 68.4 for nongeographic atrophy; and 62.9 for geographic atrophy, hemorrhage, RPE tear, or scar (P < 0

121 0 [95% CI, 1.20-4.15]; P = .01) but not pure geographic atrophy (HR, 0.66 [95% CI, 0.25-1.95]; P = .4

122 um (RPE) atrophy/absence in 22.9%, subfoveal geographic atrophy in 2.5%, and fluid in or under the re

123 um detachment (DPED) is a known precursor to geographic atrophy in age-related macular degeneration (

124 ntiated umbilical cells for the treatment of geographic atrophy in age-related macular degeneration.

125 ational drugs, and clinical trials targeting geographic atrophy in age-related macular degeneration.

126 gents are under development for treatment of geographic atrophy in both pre and early-phase clinical

127 obtaining an accurate timeline of incipient geographic atrophy in clinic populations and for quantif

128 Geographic atrophy in the fellow eye, hemorrhage, and ab

129 rected visual acuity, drusen progression, or geographic atrophy in the study eye were observed throug

130 macular degeneration (neovascular or central geographic atrophy) in one eye should consider taking th

131 Geographic atrophy incidence and growth rate.

132 Isolated geographic atrophy independent of CNV can develop in pse

133 Eight eyes (20%) of 5 patients had geographic atrophy independent of CNV.

134 Geographic atrophy is a blinding form of age-related mac

135 Geographic atrophy is defined by the presence of sharply

136 Geographic atrophy lesion size increased from 8.88 mm(2)

137 Geographic atrophy may be detected earlier by the use of

138 Areas of interest in patients with geographic atrophy measured from baseline to month 12 by

139 ers (95% CI, 6.7-10.7), eyes with noncentral geographic atrophy (n = 70) gained 8.9 letters (95% CI,

140 mediate (n = 5), and advanced stages of AMD (geographic atrophy, n = 5; neovascular disease, n = 13)

141 8-12.1), and eyes with advanced AMD (central geographic atrophy, neovascular disease, or both; n = 32

142 omography (OCT) imaging can identify nascent geographic atrophy (nGA) in eyes with intermediate age-r

143 These characteristics were termed "nascent geographic atrophy" (nGA), describing features that port

144 and concomitant vision loss associated with geographic atrophy of the macula.

145 at the 5-year follow-up examination of pure geographic atrophy or exudative macular degeneration, an

146 Analysis of the combined geographic atrophy or neovascular AMD cases in the NEI,

147 RPE of eyes affected by geographic atrophy or neovascular AMD exhibited NLRP3 st

148 an ocular tissue sections from patients with geographic atrophy or neovascular AMD were stained for N

149 graded for development of late AMD (central geographic atrophy or neovascular AMD) or pseudophakia.

150 rmediate disease, and 222 with advanced AMD (geographic atrophy or neovascular AMD).

151 Late ARM was defined as presence of either geographic atrophy or neovascular ARM.

152 ls, of which 279 progressed to advanced AMD (geographic atrophy or neovascular disease) and 1167 did

153 of whom 294 progressed to advanced stages of geographic atrophy or neovascular disease.

154 retinal tissue complex on OCT, and subfoveal geographic atrophy or scar on FP/FA had the worst VA.

155 ssociated with the 10-year incidence of pure geographic atrophy (OR per 0.1 mm IMT, 1.31; CI, 1.05-1.

156 , 0.90-2.48 and 1.39-4.90, respectively) and geographic atrophy (OR, 2.57 and 4.52; 95% CI, 0.99-6.71

157 se (OR, 6.1; 95% CI, 3.3-11.2) compared with geographic atrophy (OR, 3.0; 95% CI, 1.4-6.5) relative t

158 mediate AMD), grade 4 (central or noncentral geographic atrophy), or grade 5 (neovascular disease).

159 nsive intermediate drusen, any large drusen, geographic atrophy, or evidence of exudative maculopathy

160 e-8 expression in the RPE of human eyes with geographic atrophy, our findings provide a rationale for

161 as associated more frequently with patchy or geographic atrophy (P = .019).

162 r neovascularization (P = 0.042) but not for geographic atrophy (P = 0.47).

163 As knowledge of geographic atrophy pathophysiology advances, targeted ph

164 a 49% increase in the risk of advanced AMD (geographic atrophy plus neovascularization) for persons

165 Geographic atrophy presented as a single lesion in 89 (7

166 The Geographic Atrophy Progression (GAP) study was designed

167 Main outcome measures included incidence of geographic atrophy, progression over time, and macular f

168 VA; scar; geographic atrophy; retinal thickness, fluid; and number

169 Of these 38 eyes, 23 (60%) had geographic atrophy secondary to age-related macular dege

170 clinical investigation for the treatment of geographic atrophy secondary to age-related macular dege

171 cular degeneration (AMD) and 2 eyes (5%) had geographic atrophy secondary to pattern dystrophy.

172 h lesions associated with neovascular AMD or geographic atrophy should be considered to have late AMD

173 Europeans had a higher prevalence of geographic atrophy subtype (1.11%, 95% CrI 0.53-2.08) th

174 Geographic atrophy that formed in areas previously occup

175 in the retinal pigment epithelium mimicking geographic atrophy, the blinding end-stage condition cha

176 oroidal neovascularization area, presence of geographic atrophy, total foveal thickness </=325 mum or

177 ial depigmentation, neovascular lesions, and geographic atrophy using the modified Wisconsin Age-Rela

178 ial depigmentation, neovascular lesions, and geographic atrophy using the modified Wisconsin Age-Rela

179 ere stratified by AMD severity (early versus geographic atrophy versus neovascular), the inverse asso

180 Geographic atrophy was defined according to the Revised

181 mum were found in 24.1% (95% CI, 22.5-25.8), geographic atrophy was found in 1.0% of participants (95

182 A higher prevalence of geographic atrophy was observed among patients carrying

183 Geographic atrophy was present in 213 of 515 (41%) grada

184 ction threshold of the eyes with extrafoveal geographic atrophy was significantly higher than that of

185 However, persons who had geographic atrophy were more likely to have large drusen

186 ly AMD, and late AMD (exudative AMD and pure geographic atrophy) were 618.8 (195.5), 634.2 (206.4), a

187 and advanced AMD (neovascular AMD or central geographic atrophy) were evaluated using annual fundus p

188 Six patients with bilateral geographic atrophy who were using an eccentrically locat